Most oncologists and hematologists regard immunological subtypes as important prognostic factors, with cortical CD1a(+) T-ALL/LBL having a considerably better prognosis than early-T or mature T-ALL/LBL [12]. The gene discussed is CD1A; the disease is acute lymphoblastic leukemia.